BioXcel Therapeutics (BTAI)

• Market cap: $75.1M
• 1 day: 3.61%
• 5 days: 4.45%
• 1 month: 185.08%
• 3 months: 271.22%
• 6 months: 186.67%
• Year to date: -17.70%
• 1 year: -54.42%
• 5 years: -99.17%
• 10 years: -97.08%
• Sector: Healthcare
• Industry: Biotechnology

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 37

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

275% more call options, than puts

Call options by funds: $15K | Put options by funds: $4K

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

54% more capital invested

Capital invested by funds: $770K [Q1] → $1.19M (+$419K) [Q2]

13% more funds holding

Funds holding: 30 [Q1] → 34 (+4) [Q2]

1.15% less ownership

Funds ownership: 11.52% [Q1] → 10.37% (-1.15%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 94% upside
• Avg. target: $38 636% upside
• High target: $66 1,179% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	94% upside $10	Buy Reiterated	19 Aug 2025
LUCID CAPITAL MARKETS Elemer Piros	1,179% upside $66	Buy Reiterated	15 Jul 2025